Altimmune (ALT) said Wednesday that data from the phase 2b trial of pemvidutide to treat liver disease demonstrated improvements across non-invasive tests of metabolic dysfunction-associated steatohepatitis activity and fibrosis at 24 weeks compared with placebo.

AI-based pathology showed that pemvidutide treatment led to considerable reductions in fibrosis values compared with placebo, according to a statement.

The company will start patient enrollment for its phase 3 trial of the drug in H2 based on the latest phase 2b results, according to the company.

Price: 2.99, Change: +0.06, Percent Change: +2.05